| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 25 | | | |
| | | | 26 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 32 | | | |
| | | | 32 | | | |
| | | | 32 | | | |
| | | | 33 | | | |
| | | | 34 | | | |
| | | | 39 | | | |
| | | | 39 | | | |
| | | | 40 | | | |
| | | | 41 | | | |
| | | | 41 | | | |
| | | | 42 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | 45 | | | |
| | | | 45 | | |
| | |
Page
|
| |||
| | | | 45 | | | |
| | | | 46 | | | |
| | | | 46 | | | |
| | | | 48 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 50 | | | |
| | | | 53 | | | |
| | | | 53 | | | |
| | | | 55 | | | |
| | | | 57 | | | |
| | | | 58 | | | |
| | | | 60 | | | |
| | | | 60 | | | |
| | | | 61 | | | |
| | | | 61 | | | |
| | | | 65 | | | |
| | | | 66 | | | |
| | | | 67 | | | |
| | | | 67 | | | |
| | | | 68 | | | |
| | | | 69 | | | |
| | | | 72 | | | |
| | | | 72 | | | |
| | | | 73 | | | |
| | | | 73 | | | |
| | | | A-1 | | | |
| | | | B-1 | | |
| | Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies. | | |
Proposal
|
| |
Description
|
| |
Vote Required
|
| |
Discretionary
Voting Allowed |
|
No. 1 | | | Election of Nine Directors | | | Plurality | | |
No
|
|
No. 2 | | | Advisory Vote on Named Executive Officers’ Compensation | | | Majority Present & Entitled to Vote | | |
No
|
|
No. 3 | | | Ratification of the Selection of Ernst & Young LLP as Independent Registered Public Accounting Firm for 2019 | | | Majority Present & Entitled to Vote | | |
Yes
|
|
No. 4 | | | Amendment to the 2018 Plan | | | Majority Present & Entitled to Vote | | |
No
|
|
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Anthony E. Altig
|
| |
63
|
| |
2012
|
| | Mr. Altig joined our Board in January 2012. From 2008 to December 2017, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporation (formerly OccuLogix, Inc.), a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Mr. Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant (inactive). Among other experiences, qualifications, attributes and skills, Mr. Altig’s extensive management experience and financial expertise, as well as his experience serving on the boards of directors of several public pharmaceutical and healthcare companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Mark Auerbach | | |
80
|
| |
2010
|
| | Mr. Auerbach joined our Board in November 2010. From April 2013 until June 2016, Mr. Auerbach was the chairman of the audit committee of RCS Capital Corporation (NYSE: RCAP), a publicly traded financial services company. From December 2014 until June 2016, Mr. Auerbach was non-executive chairman of the board of RCS Capital Corporation. Mr. Auerbach previously served as lead independent director and chairman of the audit committee of Optimer Pharmaceuticals, Inc., a public company, from 2005 until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. From January 2006 through March 2010, Mr. Auerbach served as the chairman of the board of directors for Neuro Hitech, Inc., an early stage pharmaceutical company specializing in brain degenerative diseases. Over the last 20 years, Mr. Auerbach also has served as a director for several other companies, including Par Pharmaceutical Companies, Inc., a publicly traded manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical, Inc. From 1993 to 2005, Mr. Auerbach served as chief financial officer of Central Lewmar LLC, a national fine paper distributor. Mr. Auerbach received his B.S. degree in accounting from Rider University. Among other experiences, qualifications, attributes and skills, Mr. Auerbach’s extensive financial experience, his accounting degree and his experience as a director of several public companies, including his service as the chair of the audit committee of one of those public companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Richard D. DiMarchi, Ph.D. | | |
66
|
| |
2014
|
| | Dr. DiMarchi joined our Board in July 2014 upon the closing of the Assembly Pharmaceuticals, Inc. acquisition through its merger with a wholly owned subsidiary of Assembly (the Merger). Dr. DiMarchi is a co-founder of Assembly Pharmaceuticals, Inc. and served on its board from its inception in 2012 through the Merger. Dr. DiMarchi is a Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University (but currently on leave of absence until January 2020) and serves as Vice President of Research at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, Inc. and Marcadia Biotech Inc. (until it was acquired by Roche in 2010). Dr. DiMarchi was a founder of Calibrium LLC, which was acquired by Novo Nordisk in 2015 and advisor to Twilight Ventures. Dr. DiMarchi retired as Group Vice President at Eli Lilly & Company, where he provided leadership for more than two decades in biotechnology, endocrine research, and product development. Dr. DiMarchi previously served as a board member of the biotechnology trade group BIO, Ionis Pharmaceuticals, Inc. (f/k/a Isis Pharmaceuticals, Inc.) and Millennium BioTherapeutics, Inc. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemical biotechnology. Dr. DiMarchi contributed significantly to the discovery of Humalog® and to the commercial development of pharmaceutical products Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo®, and Evista®. Dr. DiMarchi is the recipient of numerous prestigious awards and in 2014 was inducted to the National Inventors Hall of Fame and in 2015 to the National Academy of Medicine. Dr. DiMarchi received a B.S. with honors from Florida Atlantic University and his Ph.D. in Biochemistry from Indiana University, and completed his postdoctoral studies at the Rockefeller University. Among other experiences, qualifications, attributes and skills, Dr. DiMarchi’s scientific training, extensive experience in the pharmaceutical industry, as well as his experience serving on the board of directors of several private pharmaceutical companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Myron Z. Holubiak | | |
72
|
| |
2010
|
| | Mr. Holubiak joined our Board in July 2010. Since March 2016 Mr. Holubiak has served as President, Chief Executive Officer and a director of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late stage drug development company focused on critical care drug products. From September 2014 until March 2016, Mr. Holubiak was the founder and Chief Executive Officer and President of Leonard-Meron Biosciences, Inc., which merged with Citius Pharmaceuticals, Inc. in March 2016. Mr. Holubiak is the former President of Roche Laboratories, Inc., USA, a major research-based pharmaceutical company, a position he held from December 1998 to August 2001. Prior to that, he held many sales and marketing positions at Roche Laboratories during his 19-year tenure there. From September 2002 until June 2016, Mr. Holubiak served on the board of directors of BioScrip, Inc., a publicly traded company and a leading home infusion provider with nationwide pharmacy and nursing capabilities and was chairman of the board of Bioscrip, Inc. from April 2012 until June 2016. Mr. Holubiak was president of 1-800-DOCTORS, Inc., a private physician finder company, from May 2007 to January 2014 and a member of its board of directors until September 2017. Since July 2015, Mr. Holubiak also has been a member of the board of directors of bioAffinity Technologies, Inc., a private cancer screening and diagnostics company. From October 2012 until October 2014, Mr. Holubiak served as a director of Intellicell Biosciences, Inc., a publicly traded regenerative medicine company. From April 2013 to April 2015, Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation. Mr. Holubiak received his B.S. in Molecular Biology and Biophysics from the University of Pittsburgh. Mr. Holubiak has received advanced business training from the Harvard Business School, the London School of Economics and the Centre for Health Economics at the University of York. Among other experiences, qualifications, attributes and skills, Mr. Holubiak’s extensive experience managing pharmaceutical and healthcare companies led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Helen S. Kim | | |
56
|
| |
2018
|
| | Ms. Kim joined our Board in March 2018. Since March 2018, Ms. Kim has been a partner at The Column Group, a science-driven venture capital firm that invests in private companies. From November 2014 until January 2018, Ms. Kim served as executive vice president of business development at Kite Pharma, Inc. where she led all business and corporate development initiatives including its sale to Gilead in September 2017. From January 2012 to January 2014, Ms. Kim served as strategic advisor to NGM Biopharmaceuticals, Inc. and from August 2009 to January 2012, Ms. Kim served as chief business officer of NGM Biopharmaceuticals, Inc. Ms. Kim’s additional industry experience includes executive positions at Kosan Biosciences, Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. and Chiron Corporation. In addition to her industry experience, from August 2003 to November 2007, Ms. Kim served as chief program officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director on the board of Exicure, Inc., a public company, and Applied Molecular Transport Inc. and Peloton Therapeutics, Inc. Ms. Kim formerly served as a director and member of the audit committee of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) and WCCT Global, Inc. and a director of Foresight Labs, VISION 4. Ms. Kim received a B.S. in Chemical and Biomedical Engineering from Northwestern University and an M.B.A. from the University of Chicago. Among other experiences, qualifications, attributes and skills, Ms. Kim’s extensive experience in leadership roles in biotechnology companies led to the conclusion of our Board that she should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Alan J. Lewis, Ph.D. | | |
73
|
| |
2015
|
| | Dr. Lewis joined our Board in December 2015. Since March 2015, Dr. Lewis has served as Chief Executive Officer and director of DiaVacs, Inc., a biotechnology company that offers dendritic cell therapy for autoimmunity and juvenile diabetes. From October 2012 to March 2014, Dr. Lewis was Chief Executive Officer and a director of Medistem, Inc., a publicly traded biotechnology company, and developer of stem cell therapies that was acquired by Intrexon Corporation. From July 2010 until November 2011, Dr. Lewis was Chairman, President and Chief Executive Officer of cancer drug developer Ambit Biosciences, Inc., which was subsequently acquired by Daiichi Sankyo Company, Limited. From January 2009 until June 2010, Dr. Lewis was President and Chief Executive Officer of the Juvenile Diabetes Research Foundation. From February 2006 until December 2008, Dr. Lewis was President and Chief Executive Officer of stem cell company Novocell, Inc., a privately held regenerative disease biotechnology company. Prior to that, Dr. Lewis served as Chief Executive Officer and a director of Signal Pharmaceuticals until its acquisition by Celgene Corporation. Dr. Lewis was named President of Celgene’s Signal Research division in San Diego, where he directed its integrated drug discovery program in oncology and inflammation and served on Celgene’s corporate executive committee. Dr. Lewis is on the board of directors for BioMarin Pharmaceuticals, Inc., where he chairs the science and technology committee and Scancell Holdings Plc, where he serves on the audit committee and remuneration committee. Dr. Lewis holds a B.Sc. in Physiology and Biochemistry from Southampton University and a Ph.D. in Pharmacology from the University of Wales, and he completed his postdoctoral training at Yale University. Among other experiences, qualifications, attributes and skills, Dr. Lewis’ extensive experience in management and the operation of pharmaceutical and healthcare companies and his scientific background, together with his experience serving on the board of directors of a public company and several private biotechnology companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Susan Mahony, Ph.D. | | |
54
|
| |
2017
|
| | Dr. Mahony joined our Board in December 2017. From 2011 until her retirement in August 2018, Dr. Mahony served as Senior Vice President and President of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company (Lilly). Prior to that, from 2000 until 2011, Dr. Mahony served in a variety of leadership roles at Lilly, including Senior Vice President Human Resources and Diversity, President and General Manager Lilly Canada, and Executive Director Global Development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995, and at Schering Plough from 1989 to 1991. Dr. Mahony earned a B.Sc. and Ph.D. in pharmacy and was awarded an Honorary Doctorate from Aston University, and she earned an M.B.A. from London Business School. Because of these and other professional experiences, Dr. Mahony possesses particular knowledge and experience in all aspects of corporate functions and company operations that strengthen the Board’s collective qualifications, skills and experience. Among other experiences, qualifications, attributes and skills, Dr. Mahony’s extensive experience in management at public pharmaceutical companies led to the conclusion of our Board that she should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
William R. Ringo, Jr.
|
| |
73
|
| |
2014
|
| | Mr. Ringo became a director upon the closing of the Merger in July 2014 and became non-executive Chairman of the Board in February 2015. From July 2010 until December 2015, Mr. Ringo was a senior advisor with Barclays Capital, the global investment banking division of Barclays Bank PLC. From July 2010 until December 2015, Mr. Ringo served as a strategic advisor with Sofinnova Ventures, a life sciences-focused investment firm. Prior to his advisory roles with Barclays Capital and Sofinnova Ventures, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer Inc., a biopharmaceutical company, from April 2008 until his retirement in April 2010. From 2004 to 2006, Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc. Mr. Ringo served on the Onyx Pharmaceuticals, Inc. board of directors from February 2011 until the October 2013 acquisition by Amgen, Inc. From 2001 to 2007, he served on various boards of directors, including: Encysive Pharmaceuticals, Inc.; Inspire Pharmaceuticals, Inc.; and InterMune, Inc., where he was the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003. From 1994 to 2002, he served as a director and chairman of the board for Community Health Systems, Inc. His experience in the global pharmaceutical sector also includes nearly 30 years with Eli Lilly and Company (Lilly). Over the course of his career with Lilly, Mr. Ringo served in numerous executive roles, including Product Group President for oncology and critical care, President of internal medicine products, President of the infectious diseases business unit, and Vice President of sales and marketing for U.S. pharmaceuticals. He also was a member of Lilly’s operating committee. Mr. Ringo is a director of Immune Design Corp., Dermira, Inc. and Five Prime Therapeutics, Inc. In the last five years, Mr. Ringo has also served as a director of Sangamo Biosciences, Inc. and Mirati Technologies, Inc. Mr. Ringo received a B.S. in business administration and an M.B.A. from the University of Dayton. Among other experience, qualifications, attributes and skills, Mr. Ringo’s extensive management experience in the pharmaceutical industry and experience in the capital markets, as well as his experience serving on the boards of directors of public pharmaceutical companies and on the boards of directors of several private pharmaceutical companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Director
Since |
| |
Business Experience
|
|
Derek A. Small | | |
43
|
| |
2014
|
| | Mr. Small has served as our President and Chief Executive Officer since February 2015. Upon the closing of the Merger, Mr. Small joined us as a director and our President and Chief Operating Officer. Mr. Small co-founded Assembly Pharmaceuticals, Inc. and served as its Executive Chairman from its inception in 2012 and Chief Executive Officer beginning in January 2014. From March 2008 to January 2014, Mr. Small served as a founding director, President, and Chief Executive Officer of Naurex, Inc., a privately-held biotechnology company developing novel therapies for central nervous system (CNS) disorders whose clinical assets were acquired by Allergan Pharmaceuticals International Limited in 2014. At Naurex, Mr. Small spearheaded the development of a rapidly acting novel antidepressant drug, Rapastinel, which has since been granted “breakthrough” designation from the FDA. Naurex’s preclinical programs formed the basis for a spinout CNS company, Aptinyx, Inc. From January 2009 to April 2012, Mr. Small also served as a founding director, President, and Chief Executive Officer of Coferon, Inc., a privately-held biotechnology company, which is developing a novel self-assembling chemistry platform. Assembly Pharmaceuticals, Naurex/Aptinyx and Coferon are portfolio enterprises of Luson Bioventures, LLC, a biotechnology and biopharmaceutical venture creation firm that Mr. Small founded in 2007 and continues to head. Mr. Small received his B.S. in Business from Franklin College and studied global business at the Harlaxton College affiliate program in England. Among other experience, qualifications, attributes and skills, Mr. Small’s extensive management experience in the pharmaceutical industry, as well as his experience serving on the board of directors of several private pharmaceutical companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure. | |
| | |
Independent
|
| |
Audit
Committee |
| |
Compensation
Committee |
| |
Nominating and
Governance Committee |
| |
Science and
Technology Committee |
| |||||||||||||||
Number of Meetings in 2018
|
| | | | | | | | | | 6 | | | | | | 9 | | | | | | 4 | | | | | | 3 | | |
Anthony E. Altig+
|
| | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | | | |
Mark Auerbach+
|
| | | | ✓ | | | | | | ✓** | | | | | | ✓ | | | | | | | | | | | | | | |
Richard D. DiMarchi, Ph.D.
|
| | | | ✓ | | | | | | | | | | | | | | | | | | | | | | | | ✓** | | |
Myron Z. Holubiak
|
| | | | ✓ | | | | | | | | | | | | ✓** | | | | | | ✓ | | | | | | | | |
Helen S. Kim††
|
| | | | ✓ | | | | | | | | | | | | | | | | | | | | | | | | ✓ | | |
Alan J. Lewis, Ph.D.
|
| | | | ✓ | | | | | | | | | | | | | | | | | | ✓** | | | | | | ✓ | | |
Susan Mahony, Ph.D.
|
| | | | ✓ | | | | | | | | | | | | ✓† | | | | | | | | | | | | ✓ | | |
William R. Ringo, Jr.*
|
| | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | |
Derek A. Small
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Director Position
|
| |
Annual Cash
Compensation(1) |
| |||
All Non-Employee Directors
|
| | | $ | 37,917(2) | | |
Chair of the Board
|
| | | $ | 30,000 | | |
Audit Committee Chair
|
| | | $ | 15,000 | | |
Service on Audit Committee (other than as Chair)
|
| | | $ | 7,500 | | |
Chair of Nominating & Governance, Compensation or Science and Technology Committees
|
| | | $ | 10,000 | | |
Service on Nominating & Governance, Compensation or Science and Technology Committees (other than as Chair)
|
| | | $ | 5,000 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($)(1) |
| |
Option
Awards ($)(2)(3) |
| |
Total
($) |
| |||||||||
Anthony E. Altig
|
| | | | 50,417 | | | | | | 210,648 | | | | | | 261,065 | | |
Mark Auerbach
|
| | | | 57,917 | | | | | | 210,648 | | | | | | 268,565 | | |
Richard D. DiMarchi, Ph.D.
|
| | | | 47,917 | | | | | | 210,648 | | | | | | 258,565 | | |
Myron Z. Holubiak
|
| | | | 52,917 | | | | | | 210,648 | | | | | | 263,565 | | |
Helen S. Kim(4)
|
| | | | 35,583 | | | | | | 1,024,616 | | | | | | 1,060,199 | | |
Alan J. Lewis, Ph.D.
|
| | | | 52,917 | | | | | | 210,648 | | | | | | 263,565 | | |
Susan Mahony, Ph.D.(5)
|
| | | | 45,833 | | | | | | 210,648 | | | | | | 256,481 | | |
William R. Ringo, Jr.
|
| | | | 80,417 | | | | | | 210,648 | | | | | | 291,065 | | |
Fees
|
| |
2018
|
| |
2017
|
| ||||||
Audit Fees(1)
|
| | | $ | 809,895 | | | | | $ | 499,000 | | |
Audit-Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees(2)
|
| | | | 131,072 | | | | | | 128,947 | | |
All Other Fees(3)
|
| | | | 25,000 | | | | | | 3,000 | | |
Total
|
| | | $ | 965,967 | | | | | $ | 630,947 | | |
|
| | |
Options
|
| |
Stock Awards
|
| ||||||||||||||||||
Name and Position
|
| |
Weighted
Average Exercise Price ($) |
| |
Number of
Awards (#) |
| |
Dollar Value
($)(1) |
| |
Number of
Awards (#) |
| ||||||||||||
Derek A. Small,
President and Chief Executive Officer |
| | | | 19.69 | | | | | | 65,000 | | | | | | 639,925 | | | | | | 32,500 | | |
Graham Cooper,
Chief Financial Officer and Chief Operating Officer |
| | | | 19.69 | | | | | | 35,000 | | | | | | 2,763,575 | | | | | | 117,500 | | |
Richard J. Colonno, Ph.D.,
Executive Vice President and Chief Scientific Officer of Virology Operations |
| | | | 19.69 | | | | | | 32,500 | | | | | | 803,763 | | | | | | 36,250 | | |
Uri A. Lopatin, M.D.,
Chief Medical Officer |
| | | | 19.69 | | | | | | 27,500 | | | | | | 270,738 | | | | | | 13,750 | | |
Jacqueline S. Papkoff, Ph.D.,
Senior Vice President, Chief Scientific Officer Microbiome |
| | | | 21.65 | | | | | | 48,750 | | | | | | 527,756 | | | | | | 24,375 | | |
David J. Barrett,
Former Chief Financial Officer and Chief Operating Officer |
| | | | N/A | | | | | | 0 | | | | | | N/A | | | | | | 0 | | |
| | |
Options
|
| |
Stock Awards
|
| ||||||||||||||||||
Name and Position
|
| |
Weighted
Average Exercise Price ($) |
| |
Number of
Awards (#) |
| |
Dollar Value
($)(1) |
| |
Number of
Awards (#) |
| ||||||||||||
All current executive officers, as a group | | | | | 20.15 | | | | | | 208,750 | | | | | | 5,005,757(2) | | | | | | 224,375 | | |
All current directors who are not executive officers, as a group(3) | | | | | N/A | | | | | | 0 | | | | | | N/A(2) | | | | | | 0 | | |
All current employees who are not executive officers, as a group(4)
|
| | | | 23.32 | | | | | | 573,999 | | | | | | 4,688,616(2) | | | | | | 216,553 | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted average
exercise price of outstanding options, warrants and rights (1) (b) |
| |
Number of
securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) |
| |||||||||
Equity compensation plans approved by our
stockholders |
| | | | 4,668,900(2) | | | | | $ | 13.57 | | | | | | 1,874,064(3) | | |
Equity compensation plans not approved by our stockholders
|
| | | | 551,546(4) | | | | | $ | 44.69 | | | | | | 259,228 | | |
Total
|
| | | | 5,205,446 | | | | | | | | | | | | 2,133,292 | | |
|
Name
|
| |
Age (as of
3/22/19) |
| |
Business Experience
|
|
Graham Cooper | | |
49
|
| | Mr. Cooper joined as Chief Financial Officer and Chief Operating Officer in March 2018. Mr. Cooper was the Chief Financial Officer of Receptos, Inc. (Receptos) from February 2013 until Receptos was acquired by Celgene Corporation in August 2015. Following Celgene’s acquisition of Receptos and before joining us, Mr. Cooper served as a consultant and director to various other biotechnology companies. In 2012, Mr. Cooper was the Executive Vice President, Finance and Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Mr. Cooper served as Senior Vice President, Chief Financial Officer and Treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From August 1992 to January 1995, he worked as an accountant at Deloitte & Touche, and was previously a C.P.A. Mr. Cooper currently serves on the Board of Directors for Kezar Life Sciences, Inc. (Nasdaq: KZR) and Unity Biotechnology, Inc. (Nasdaq: UBX) and Bioniz Therapeutics, Inc., a privately-held company. Mr. Cooper holds a B.A. in Economics from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. | |
Richard J. Colonno, Ph.D. | | |
69
|
| | Dr. Colonno is our Executive Vice President and Chief Scientific Officer of Virology Operations. Dr. Colonno joined as Chief Scientific Officer in January 2016 and became Executive Vice President and Chief Scientific Officer of Virology Operations in January 2018. Dr. Colonno has been instrumental in the discovery and development of multiple approved antiviral drugs, including Baraclude® and Reyataz®. From September 2007 to January 2016, Dr. Colonno was the Chief Science Officer of Presidio Pharmaceuticals, Inc., where he directed its hepatitis C (HCV) antiviral programs, including the discovery and development of the HCV NS5A inhibitor ravidasvir. From June 1991 to August 2007, Dr. Colonno was Vice President, Infectious Diseases Drug Discovery at Bristol-Myers Squibb Co., where he played a pivotal role in building Bristol-Myers Squibb’s antiviral franchise. From August 1982 to May 1991, he was Senior Director of Antiviral Research at Merck Research Labs. Dr. Colonno received a B.A. | |
Name
|
| |
Age (as of
3/22/19) |
| |
Business Experience
|
|
| | | | | | in Biology and Chemistry from Kansas Wesleyan University and a Ph.D. in Microbiology from the University of Kansas and has co-authored more than 160 scientific articles. | |
Uri A. Lopatin, M.D. | | |
47
|
| | Dr. Lopatin joined as Chief Medical Officer and Vice President Research and Development in July 2014 upon the closing of the Merger. Prior to the Merger, Dr. Lopatin was Chief Medical Officer and Vice President Research and Development, a position he held since October 2012. Prior to that, he was a Senior Director for Clinical and Translational Research – Liver Disease at Gilead Sciences, Inc. from October 2010 to September 2012 and a Translational Medical Leader at Roche from May 2008 to September 2010. He has designed and coordinated preclinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, particularly on hepatitis B and immunology and is a co-author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his Infectious Disease Board certification following fellowship training in Infectious Disease at the National Institute of Health, and he received internal medicine board certification following completion of residency at New York University. Dr. Lopatin received a B.S. in Biology, cum laude with distinction, from Cornell University and received his M.D. degree from the University of Medicine and Dentistry of New Jersey — New Jersey Medical School, where he was awarded the Stanley S. Bergen medal of excellence. | |
Jacqueline S. Papkoff, Ph.D. | | |
63
|
| | Dr. Papkoff joined as Senior Vice President, Chief Scientific Officer Microbiome in April 2018. Dr. Papkoff was Senior Vice President, Research at Evelo Biosciences, Inc. from May 2016 to October 2017. From January 2013 to May 2016, Dr. Papkoff was Vice President, Immunology Scientific Innovation at Johnson & Johnson California Innovation Center as a representative of the Janssen immunology therapeutic area. From 2008 to 2012, Dr. Papkoff was an independent biotherapeutic research and development consultant to biotech and pharmaceutical companies. In 2006 and 2007, Dr. Papkoff was Executive Vice President Therapeutics, Chief Scientific Officer at CFD Therapeutics, Inc. From 2002 until 2006, Dr. Papkoff was initially Vice President, Discovery and later Executive Vice President, Therapeutics at diaDexus, Inc. Dr. Papkoff received a B.A. in Biology with highest honors from the University of California, Santa Cruz and received a Ph.D. in Biology from the University of California, San Diego. | |
What We Do
|
| |
What We Don’t Do
|
|
✓
Annual performance-based cash bonus opportunities tied to individual and Company-wide performance
|
| |
✗
No guaranteed bonuses
|
|
✓
Equity grants have multi-year vesting requirements
|
| |
✗
No tax gross-ups
|
|
✓
Time-based equity grants have minimum vesting period of one year
|
| |
✗
No special retirement plans for executives
|
|
✓
Compensation Committee is entirely independent
|
| |
✗
No special health or welfare benefits
|
|
✓
Use an independent compensation consultant
|
| |
✗
No hedging of our stock
|
|
✓
Double-trigger severance and equity acceleration rights
|
| |
✗
No pledging of our stock without pre-approval
|
|
✓
Limited perquisites
|
| |
Name
|
| |
Title
|
|
Derek A. Small
|
| | President and Chief Executive Officer | |
Graham Cooper(1)
|
| | Chief Financial Officer and Chief Operating Officer | |
Richard J. Colonno, Ph.D.
|
| | Executive Vice President and Chief Scientific Officer of Virology Operations | |
Uri A. Lopatin, M.D.
|
| | Chief Medical Officer | |
Jacqueline S. Papkoff, Ph.D.
|
| | Senior Vice President, Chief Scientific Officer Microbiome | |
David J. Barrett(1)
|
| | Former Chief Financial Officer and Chief Operating Officer | |
| Achillion Pharmaceuticals, Inc.* | | | CytomX Therapeutics, Inc.* | | | Protagonist Therapeutics, Inc.* | |
| Arbutus Biopharma Corp. | | | Editas Medicine, Inc. | | | REGENXBIO Inc.* | |
| Audentes Therapeutics, Inc. | | | Five Prime Therapeutics, Inc.* | | | Sangamo Therapeutics, Inc. | |
| AveXis, Inc.* | | | Ignyta, Inc. | | | Selecta Biosciences, Inc.* | |
| Bellicum Pharmaceuticals, Inc. | | | Immune Design Corp. | | | Seres Therapeutics, Inc.* | |
| Calithera Biosciences, Inc. | | | Iovance Biotherapeutics, Inc.* | | | Wave Life Sciences Ltd.* | |
| Chimerix, Inc.* | | | Mirati Therapeutics, Inc. | | |
NEO
|
| |
2017
|
| |
2018
|
| |
Percentage
Increase |
| |||||||||
Derek A. Small
|
| | | $ | 475,000 | | | | | $ | 525,000 | | | | | | 10.5% | | |
Graham Cooper(1)
|
| | | | — | | | | | | 425,000 | | | | | | — | | |
Richard J. Colonno, Ph.D.
|
| | | | 391,400 | | | | | | 410,000 | | | | | | 4.8% | | |
Uri A. Lopatin, M.D.
|
| | | | 367,500 | | | | | | 390,000 | | | | | | 6.1% | | |
Jacqueline S. Papkoff, Ph.D.(2)
|
| | | | — | | | | | | 360,000 | | | | | | — | | |
| | |
2017 Target Bonus
|
| |
2017 Actual Bonus
|
| |
2018 Target Bonus
|
| |
2018 Actual Bonus
|
| ||||||||||||||||||||||||||||||||||||
NEO
|
| |
Percentage
of Base Salary |
| |
Amount
|
| |
Amount
|
| |
Percentage
of Target Bonus |
| |
Percentage
of Base Salary |
| |
Amount
|
| |
Amount
|
| |
Percentage
of Target Bonus |
| ||||||||||||||||||||||||
Derek A. Small
|
| | | | 50% | | | | | $ | 237,500 | | | | | $ | 250,000 | | | | | | 105% | | | | | | 50% | | | | | $ | 262,500 | | | | | $ | 279,000 | | | | | | 106% | | |
Graham Cooper(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 40% | | | | | $ | 138,507 | | | | | $ | 157,200 | | | | | | 113% | | |
Richard J. Colonno, Ph.D.
|
| | | | 40% | | | | | $ | 156,560 | | | | | | 164,000 | | | | | | 105% | | | | | | 40% | | | | | $ | 164,000 | | | | | $ | 182,000 | | | | | | 111% | | |
Uri A. Lopatin, M.D.
|
| | | | 35% | | | | | $ | 128,625 | | | | | $ | 128,700 | | | | | | 100% | | | | | | 35% | | | | | $ | 136,500 | | | | | $ | 146,400 | | | | | | 107% | | |
Jacqueline S. Papkoff(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 35% | | | | | $ | 94,500 | | | | | $ | 104,900 | | | | | | 111% | | |
David J. Barrett
|
| | | | 50% | | | | | $ | 192,500 | | | | | $ | 204,600 | | | | | | 106% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Options to Purchase Common Stock
|
| |
Restricted Stock Units
|
| ||||||||||||||||||
NEO
|
| |
Number of
Shares |
| |
Grant Date
Fair Value(1) |
| |
Number of
Shares |
| |
Grant Date
Fair Value(1) |
| ||||||||||||
Derek A. Small
|
| | | | 65,000 | | | | | $ | 2,258,020 | | | | | | 32,500 | | | | | $ | 1,597,050 | | |
Graham Cooper(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Richard J. Colonno, Ph.D.
|
| | | | 30,000 | | | | | | 1,042,163 | | | | | | 15,000 | | | | | | 737,100 | | |
Uri A. Lopatin, M.D.
|
| | | | 15,000 | | | | | | 521,082 | | | | | | 7,500 | | | | | | 368,550 | | |
Jacqueline S. Papkoff, Ph.D.(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Options to Purchase Common Stock
|
| |||||||||
NEO
|
| |
Number of
Shares |
| |
Grant Date
Fair Value(1) |
| ||||||
Derek A. Small
|
| | | | — | | | | | | — | | |
Graham Cooper
|
| | | | 220,000 | | | | | $ | 8,853,732 | | |
Richard J. Colonno, Ph.D.
|
| | | | — | | | | | | — | | |
Uri A. Lopatin, M.D.
|
| | | | — | | | | | | — | | |
Jacqueline S. Papkoff, Ph.D.
|
| | | | 106,200 | | | | | | 3,518,383 | | |
| | |
Options to Purchase Common Stock
|
| |
Restricted Stock Units
|
| ||||||||||||||||||
NEO
|
| |
Number of
Shares |
| |
Grant Date Fair
Value(1) |
| |
Number of
Shares |
| |
Grant Date Fair
Value(1) |
| ||||||||||||
Derek A. Small
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Graham Cooper
|
| | | | — | | | | | | — | | | | | | 100,000 | | | | | $ | 2,419,000 | | |
Richard J. Colonno, Ph.D.
|
| | | | — | | | | | | — | | | | | | 20,000 | | | | | | 483,800 | | |
Uri A. Lopatin, M.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Jacqueline S. Papkoff, Ph.D.
|
| | | | 21,250 | | | | | | 357,700 | | | | | | 10,625 | | | | | | 257,019 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($)(1) |
| |
Bonus
($) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(10) |
| |
Total
($) |
| ||||||||||||||||||||||||
Derek A. Small(4)
President and Chief Executive Officer |
| | | | 2018 | | | | | | 516,667 | | | | | | — | | | | | | 1,597,050 | | | | | | 2,258,020 | | | | | | 279,000 | | | | | | 95,303 | | | | | | 4,746,040 | | |
| | | 2017 | | | | | | 470,833 | | | | | | — | | | | | | — | | | | | | 717,892 | | | | | | 250,000 | | | | | | — | | | | | | 1,438,725 | | | ||
| | | 2016 | | | | | | 445,400 | | | | | | — | | | | | | — | | | | | | — | | | | | | 213,750 | | | | | | — | | | | | | 659,150 | | | ||
Graham Cooper(5)
Chief Financial Officer and Chief Operating Officer |
| | | | 2018 | | | | | | 346,266 | | | | | | — | | | | | | 2,419,000 | | | | | $ | 8,853,732 | | | | | | 157,200 | | | | | | 4,050 | | | | | | 11,780,248 | | |
Richard J. Colonno, Ph.D.(6)
Executive Vice President and Chief Scientific Officer of Virology Operations |
| | | | 2018 | | | | | | 406,900 | | | | | | — | | | | | | 1,220,900 | | | | | | 1,042,163 | | | | | | 182,000 | | | | | | 57,476 | | | | | | 2,909,439 | | |
| | | 2017 | | | | | | 389,500 | | | | | | — | | | | | | 5,313,600 | | | | | | 538,419 | | | | | | 166,400 | | | | | | — | | | | | | 6,407,919 | | | ||
| | | 2016 | | | | | | 377,320 | | | | | | 75,000(7) | | | | | | — | | | | | | 1,055,948 | | | | | | 125,000 | | | | | | — | | | | | | 1,633,268 | | | ||
Uri A. Lopatin, M.D.
Chief Medical Officer |
| | | | 2018 | | | | | | 386,250 | | | | | | — | | | | | | 368,550 | | | | | | 521,082 | | | | | | 146,400 | | | | | | 75,905 | | | | | | 1,499,187 | | |
| | | 2017 | | | | | | 364,167 | | | | | | — | | | | | | — | | | | | | 224,342 | | | | | | 128,700 | | | | | | 10,769 | | | | | | 728,394 | | | ||
| | | 2016 | | | | | | 344,167 | | | | | | — | | | | | | — | | | | | | — | | | | | | 116,000 | | | | | | — | | | | | | 460,167 | | | ||
Jacqueline S. Papkoff, Ph.D.(8)
Senior Vice President, Chief Scientific Officer Microbiome |
| | | | 2018 | | | | | | 270,000 | | | | | | — | | | | | | 257,019 | | | | | $ | 3,868,084 | | | | | | 104,900 | | | | | | 10,200 | | | | | | 4,510,203 | | |
David J. Barrett(9)
Former Chief Financial Officer and Chief Operating Officer |
| | | | 2018 | | | | | | 179,167 | | | | | | — | | | | | | 4,317,000 | | | | | | 26,924(11) | | | | | | — | | | | | | 801,095 | | | | | | 5,324,225, | | |
| | | 2017 | | | | | | 383,017 | | | | | | — | | | | | | — | | | | | | 448,683 | | | | | | 204,600 | | | | | | 30,136 | | | | | | 1,066,435 | | | ||
| | | 2016 | | | | | | 471,001 | | | | | | — | | | | | | — | | | | | | — | | | | | | 177,300 | | | | | | 30,136 | | | | | | 578,437 | | |
Name
|
| |
Year
|
| |
HSA
Contribution |
| |
401(k)
Match |
| |
Accrued and
Unused PTO |
| |
Severance
|
| |
Consulting
Fees |
| |
Total
All Other Compensation |
| |||||||||||||||||||||
Mr. Small
|
| | | | 2018 | | | | | $ | 5,400 | | | | | $ | 1,583 | | | | | $ | 88,320 | | | | | | — | | | | | | — | | | | | $ | 95,303 | | |
| | | 2017 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2016 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Mr. Cooper
|
| | | | 2018 | | | | | | 4,050 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,050 | | |
Dr. Colonno
|
| | | | 2018 | | | | | | 5,400 | | | | | | 12,749 | | | | | | 39,327 | | | | | | — | | | | | | — | | | | | | 57,476 | | |
| | | 2017 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2016 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Dr. Lopatin
|
| | | | 2018 | | | | | | 5,400 | | | | | | 18,200 | | | | | | 53,005 | | | | | | — | | | | | | — | | | | | | 75,905 | | |
| | | 2017 | | | | | | — | | | | | | — | | | | | | 10,769 | | | | | | — | | | | | | — | | | | | | 10,769 | | | ||
| | | 2016 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Dr. Papkoff
|
| | | | 2018 | | | | | | — | | | | | | 10,200 | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,200 | | |
Mr. Barrett
|
| | | | 2018 | | | | | | 5,400 | | | | | | 14,876 | | | | | | 90,822 | | | | | $ | 460,000 | | | | | $ | 230,000 | | | | | | 801,095 | | |
| | | 2017 | | | | | | — | | | | | | — | | | | | | 30,136 | | | | | | — | | | | | | — | | | | | | 30,136 | | | ||
| | | 2016 | | | | | | — | | | | | | — | | | | | | 30,136 | | | | | | — | | | | | | — | | | | | | 30,136 | | |
Name
|
| |
Plan
|
| |
Grant Date
|
| |
Estimated
Future Payouts Under Non-Equity Incentive Plan Awards Target ($) |
| |
All Other
Stock Awards: Number of Shares of Stock or Units (#) |
| |
All Other
Option Awards: Number of Securities Underlying Options (#) |
| |
Exercise
of Base Price of Option Awards ($/Sh) |
| |
Grant Date
Fair Value of Stock and Option Awards ($)(1) |
| ||||||||||||||||||
Derek A. Small
|
| |
2018 Bonus Plan
|
| | | | — | | | | | | 262,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 2014 Plan | | | | | 3/29/2018(2) | | | | | | — | | | | | | 32,500 | | | | | | — | | | | | | — | | | | | | 1,597,050 | | | ||
| 2014 Plan | | | | | 3/29/2018(3) | | | | | | — | | | | | | — | | | | | | 65,000 | | | | | | 49.14 | | | | | | 2,258,020 | | | ||
Graham Cooper
|
| |
2018 Bonus Plan
|
| | | | — | | | | | | 138,507 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 2017 Plan | | | | | 3/8/2018(4) | | | | | | | | | | | | — | | | | | | 220,000 | | | | | | 57.53 | | | | | | 8,853,732 | | | ||
| 2018 Plan | | | | | 12/12/2018(5) | | | | | | — | | | | | | 100,000 | | | | | | — | | | | | | — | | | | | | 2,419,000 | | | ||
Richard J. Colonno, Ph.D.
|
| |
2018 Bonus Plan
|
| | | | — | | | | | | 164,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 2014 Plan | | | | | 3/29/2018(2) | | | | | | — | | | | | | 15,000 | | | | | | — | | | | | | — | | | | | | 737,100 | | | ||
| 2014 Plan | | | | | 3/29/2018(3) | | | | | | — | | | | | | — | | | | | | 30,000 | | | | | | 49.14 | | | | | | 1,042,163 | | | ||
| 2018 Plan | | | | | 12/12/2018(6) | | | | | | — | | | | | | 20,000 | | | | | | — | | | | | | — | | | | | | 483,800 | | | ||
Uri A. Lopatin, M.D.
|
| |
2018 Bonus Plan
|
| | | | — | | | | | | 136,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 2014 Plan | | | | | 3/29/2018(2) | | | | | | — | | | | | | 7,500 | | | | | | — | | | | | | — | | | | | | 368,550 | | | ||
| 2014 Plan | | | | | 3/29/2018(3) | | | | | | — | | | | | | — | | | | | | 15,000 | | | | | | 49.14 | | | | | | 521,082 | | | ||
Jacqueline S. Papkoff, Ph.D.
|
| |
2018 Bonus Plan
|
| | | | — | | | | | | 94,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 2017 Plan | | | | | 4/2/2018(7) | | | | | | — | | | | | | — | | | | | | 106,200 | | | | | | 46.75 | | | | | | 3,510,383 | | | ||
| 2018 Plan | | | | | 12/12/2018(8) | | | | | | — | | | | | | 10,625 | | | | | | — | | | | | | — | | | | | | 257,019 | | | ||
| 2018 Plan | | | | | 12/12/2018(9) | | | | | | — | | | | | | — | | | | | | 21,250 | | | | | | 24.19 | | | | | | 357,700 | | | ||
David J. Barrett
|
| | 2014 Plan | | | | | 6/1/2018(10) | | | | | | — | | | | | | 100,000 | | | | | | — | | | | | | — | | | | | | 4,317,000 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||||||||
Derek A. Small
|
| | | | 466,238 | | | | | | — | | | | | | 2.22 | | | | | | 5/15/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 35,000 | | | | | | 5,000(1) | | | | | | 25.34 | | | | | | 3/29/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 65,000(2) | | | | | | 49.14 | | | | | | 3/29/2028 | | | | | | | | | | | | | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 32,500(3) | | | | | | 735,150 | | | | | | — | | | | | | — | | | ||
Graham Cooper
|
| | | | — | | | | | | 220,000(4) | | | | | | 57.53 | | | | | | 3/8/2028 | | | | | | | | | | | | | | | | | | — | | | | | | — | | |
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 100,000(5) | | | | | | 2,262,000 | | | | | | — | | | | | | — | | | ||
Richard J. Colonno, Ph.D.
|
| | | | 100,000(4) | | | | | | 100,000(6) | | | | | | 7.03 | | | | | | 1/11/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 26,250(1) | | | | | | 3,750(1) | | | | | | 25.34 | | | | | | 3/29/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 30,000(2) | | | | | | 49.14 | | | | | | 3/29/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 45,000(7) | | | | | | 1,017,900 | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 15,000(3) | | | | | | 339,300 | | | | | | — | | | | | | — | | | ||
Uri A. Lopatin, M.D.
|
| | | | 160,000 | | | | | | — | | | | | | 7.20 | | | | | | 7/10/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 10,937 | | | | | | 1,563(1) | | | | | | 25.34 | | | | | | 3/29/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 15,000(2) | | | | | | 49.14 | | | | | | 3/29/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,500(3) | | | | | | 169,650 | | | | | | — | | | | | | — | | | ||
Jacqueline S. Papkoff, Ph.D.
|
| | | | — | | | | | | 106,200(2) | | | | | | 46.75 | | | | | | 4/2/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | — | | | | | | 21,250(8) | | | | | | 24.19 | | | | | | 12/12/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,625(8) | | | | | | 240,338 | | | | | | — | | | | | | — | | | ||
David J. Barrett
|
| | | | 459,942 | | | | | | — | | | | | | 7.20 | | | | | | 7/11/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 25,000 | | | | | | — | | | | | | 25.34 | | | | | | 3/29/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 66,668(9) | | | | | | 1,508,030 | | | | | | — | | | | | | — | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of
Shares Acquired on Exercise (#) |
| |
Value
Realized on Exercise(1) ($) |
| |
Number of
Shares Acquired on Vesting (#) |
| |
Value
Realized on Vesting(2) ($) |
| ||||||||||||
Derek A. Small
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Graham Cooper
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Richard J. Colonno, Ph.D.
|
| | | | — | | | | | | — | | | | | | 95,000(3) | | | | | | 3,577,550 | | |
Uri A. Lopatin, M.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Jacqueline S. Papkoff, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David J. Barrett
|
| | | | 241,664(4) | | | | | | 10,260,848 | | | | | | 33,332(5) | | | | | | 1,096,290 | | |
Name
|
| |
Executive
Contributions in Last FY ($) |
| |
Aggregate
Balance at Last FYE ($) |
| ||||||
Derek A. Small
|
| | | | — | | | | | | — | | |
Graham Cooper
|
| | | | — | | | | | | — | | |
Richard J. Colonno, Ph.D.
|
| | | | 3,577,550 | | | | | | 3,577,550 | | |
Uri A. Lopatin, M.D.
|
| | | | — | | | | | | — | | |
Jacqueline S. Papkoff, Ph.D.
|
| | | | — | | | | | | — | | |
David J. Barrett
|
| | | | 1,096,290 | | | | | | 1,096,290 | | |
Name
|
| |
Termination
Without Cause Other Than Within 12 Months Following a Change of Control ($) |
| |
Termination
for Good Reason by Executive Other Than Within 12 Months Following Change of Control ($) |
| |
Disability
($) |
| |
Death
($) |
| |
Termination
Without Cause, Disability or for Good Reason Within 12 Months Following a Change of Control ($) |
| |||||||||||||||
Derek A. Small | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 525,000 | | | | | | 525,000 | | | | | | 525,000 | | | | | | 525,000 | | | | | | 1,181,250 | | |
Continuation of Benefits
|
| | | | 21,436 | | | | | | 21,436 | | | | | | 21,436 | | | | | | — | | | | | | 32,153 | | |
Equity Acceleration(1)
|
| | | | 183,787 | | | | | | 183,787 | | | | | | 183,787 | | | | | | — | | | | | | 735,150 | | |
Graham Cooper | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 425,000 | | | | | | 425,000 | | | | | | 425,000 | | | | | | 425,000 | | | | | | 892,500(3) | | |
Continuation of Benefits
|
| | | | 21,436 | | | | | | 21,436 | | | | | | 21,436 | | | | | | — | | | | | | 32,153 | | |
Equity Acceleration(1)
|
| | | | 565,500 | | | | | | 565,000 | | | | | | 565,500 | | | | | | — | | | | | | 2,262,000 | | |
Richard J. Colonno, Ph.D. | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 410,000 | | | | | | 410,000 | | | | | | 410,000 | | | | | | 410,000 | | | | | | 779,000 | | |
Continuation of Benefits
|
| | | | 14,892 | | | | | | 14,892 | | | | | | 14,892 | | | | | | — | | | | | | 22,338 | | |
Equity Acceleration(1)
|
| | | | 864,325 | | | | | | 864,325 | | | | | | 864,325 | | | | | | — | | | | | | 2,916,200 | | |
Name
|
| |
Termination
Without Cause Other Than Within 12 Months Following a Change of Control ($) |
| |
Termination
for Good Reason by Executive Other Than Within 12 Months Following Change of Control ($) |
| |
Disability
($) |
| |
Death
($) |
| |
Termination
Without Cause, Disability or for Good Reason Within 12 Months Following a Change of Control ($) |
| |||||||||||||||
Uri A. Lopatin, M.D. | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 390,000 | | | | | | 390,000 | | | | | | 390,000 | | | | | | 390,000 | | | | | | 526,500 | | |
Continuation of Benefits
|
| | | | 21,436 | | | | | | 21,436 | | | | | | 21,436 | | | | | | — | | | | | | 21,436 | | |
Equity Acceleration(1)
|
| | | | 42,413 | | | | | | 42,413 | | | | | | 42,413 | | | | | | — | | | | | | 169,650 | | |
Jacqueline S. Papkoff, Ph.D. | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 360,000 | | | | | | 360,000 | | | | | | 360,000 | | | | | | 390,000 | | | | | | 486,000 | | |
Continuation of Benefits
|
| | | | 10,548 | | | | | | 10,548 | | | | | | 10,548 | | | | | | — | | | | | | 10,548 | | |
Equity Acceleration(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 240,338 | | |
David J. Barrett(2) | | | | | | | |||||||||||||||||||||||||
Cash Severance
|
| | | | 421,667 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Continuation of Benefits
|
| | | | 19,649 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Equity Acceleration(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,508,030 | | |
| Submitted by: | | | The Compensation Committee Myron Z. Holubiak, Chairman Mark Auerbach Susan Mahony, Ph.D. William R. Ringo, Jr. |
|
Name of Beneficial Owner
|
| |
Shares
Beneficially Owned |
| |
Percentage
Owned (%) |
| ||||||
5% Stockholders: | | | | ||||||||||
Jennison Associates LLC(1)
466 Lexington Avenue New York, NY 10017 |
| | | | 2,478,639 | | | | | | 9.7% | | |
EcoR1 Capital, LLC(2)
409 Illinois Street San Francisco, CA 94158 |
| | | | 2,404,853 | | | | | | 9.4% | | |
Wellington Management Group LLP,(3)
Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210 |
| | | | 2,316,457 | | | | | | 9.1% | | |
BlackRock Inc.(4)
55 East 52nd Street New York, NY 10055 |
| | | | 1,909,510 | | | | | | 7.5% | | |
Directors, Named Executive Officers and Executive Officers: | | | | ||||||||||
Anthony E. Altig(5)
|
| | | | 107,000 | | | | | | * | | |
Mark Auerbach(6)
|
| | | | 99,000 | | | | | | * | | |
Richard D. DiMarchi, Ph.D.(7)
|
| | | | 418,240 | | | | | | 1.6% | | |
Myron Z. Holubiak(6)
|
| | | | 99,000 | | | | | | * | | |
Helen S. Kim(6)
|
| | | | 14,167 | | | | | | * | | |
Susan Mahony, Ph.D.(6)
|
| | | | 14,167 | | | | | | * | | |
Alan J. Lewis, Ph.D.(6)
|
| | | | 55,000 | | | | | | * | | |
William R. Ringo, Jr.(8)
|
| | | | 103,465 | | | | | | * | | |
Derek A. Small(9)
|
| | | | 1,166,358 | | | | | | 4.6% | | |
Name of Beneficial Owner
|
| |
Shares
Beneficially Owned |
| |
Percentage
Owned (%) |
| ||||||
Richard J. Colonno, Ph.D.(10)
|
| | | | 191,875 | | | | | | * | | |
Graham Cooper(11)
|
| | | | 85,556 | | | | | | * | | |
Uri A. Lopatin, M.D.(12)
|
| | | | 789,549 | | | | | | 3.1% | | |
Jacqueline S. Papkoff, Ph.D.(13)
|
| | | | 28,763 | | | | | | * | | |
David J. Barrett(14)
|
| | | | 1,369,940 | | | | | | 5.4% | | |
All directors and current executive officers as a group (13 persons)(15)
|
| | | | 3,172,139 | | | | | | 12.42% | | |
|